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A B S T R A C T   
Premorbid functioning and cognitive measures may reflect gradients of developmental impairment across 
diagnostic categories in psychosis. In this study, we sought to examine the associations of current cognition and 
premorbid adjustment with symptom dimensions in a large first episode psychosis (FEP) sample. 
We used data from the international EU-GEI study. Bifactor modelling of the Operational Criteria in Studies of 
Psychotic Illness (OPCRIT) ratings provided general and specific symptom dimension scores. Premorbid 
Adjustment Scale estimated premorbid social (PSF) and academic adjustment (PAF), and WAIS-brief version 
measured IQ. A MANCOVA model examined the relationship between symptom dimensions and PSF, PAF, and 
IQ, having age, sex, country, self-ascribed ethnicity and frequency of cannabis use as confounders. 
In 785 patients, better PSF was associated with fewer negative (B = − 0.12, 95% C.I. − 0.18, − 0.06, p < 0.001) 
and depressive (B = − 0.09, 95% C.I. − 0.15, − 0.03, p = 0.032), and more manic (B = 0.07, 95% C.I. 0.01, 0.14, p 
= 0.023) symptoms. Patients with a lower IQ presented with slightly more negative and positive, and fewer 
manic, symptoms. Secondary analysis on IQ subdomains revealed associations between better perceptual 
reasoning and fewer negative (B = − 0.09, 95% C.I. − 0.17, − 0.01, p = 0.023) and more manic (B = 0.10, 95% C. 
I. 0.02, 0.18, p = 0.014) symptoms. Fewer positive symptoms were associated with better processing speed (B =
− 0.12, 95% C.I. − 0.02, − 0.004, p = 0.003) and working memory (B = − 0.10, 95% C.I. − 0.18, − 0.01, p =
0.024). 
These findings suggest that the negative and manic symptom dimensions may serve as clinical proxies of 
different neurodevelopmental predisposition in psychosis.   
1. Introduction 
Premorbid and cognitive impairment at the first episode of psychosis 
(FEP) is associated with a worse psychosis outcome (Kravariti et al., 
2019; Rabinowitz et al., 2006, 2005; Díaz-Caneja et al., 2015). However, 
such impairment is not diagnosis-specific (Arango et al., 2014; Cole 
et al., 2012; Horton et al., 2015; Larsen et al., 2004; Parellada et al., 
2017; Sheffield et al., 2018). Although cognitive impairment in bipolar 
disorder seems to be generally more severe than in psychotic depression 
and less severe than in schizophrenia, cognitive function may also vary 
considerably among patients with the same diagnosis (Sheffield et al., 
2018; Trotta et al., 2015; Zanelli et al., 2010). 
The transdiagnostic and interindividual variability of premorbid and 
cognitive factors contributes to the well-known impossibility in setting 
neat boundaries between the categories of schizophrenia, schizo-
affective, and bipolar and major depressive disorders with psychotic 
features (Laursen et al., 2009; Upthegrove et al., 2017). 
Given that premorbid functioning and cognitive measures may 
reflect differential gradients of developmental impairment in psychosis 
(Demjaha et al., 2012a; Murray et al., 2004; Owen and O’Donovan, 
2017), a model based on continuous symptom dimensions (Quattrone 
et al., 2019; Van Os et al., 1999) would be methodologically appropriate 
for examining how these features impact psychosis expression (Guerra 
et al., 2002; Kravariti et al., 2012; Linscott and van Os, 2010). 
Previous studies using symptom dimensions have mostly focused on 
non-affective psychotic disorders. They showed an association between 
worse premorbid and cognitive factors with more negative and dis-
organised, but not positive and depressive symptoms (reviewed by de 
Gracia Dominguez et al., 2009; Ventura et al., 2010). Interestingly, one 
study including both non-affective and affective diagnosis at FEP 
confirmed that negative symptoms were associated with lower IQ and 
processing speed, while mania showed an inverted-U-shape relationship 
so that patients with intermediate levels of mania had better cognitive 
performance than those with low or high levels (Kravariti et al., 2012). 
Premorbid adjustment in schizophrenia has also been found to be worse 
in patients with more disorganised (Cohen et al., 2010) and negative 
symptoms (Bucci et al., 2018b), even when considering FEP samples 
alone (Chang et al., 2016; Grau et al., 2016; Monte et al., 2008; Stouten 
et al., 2017); whereas there is mixed evidence on the association be-
tween poor premorbid adjustment and positive symptoms (Brill et al., 
2009; Bucci et al., 2018b; Chang et al., 2016; Grau et al., 2016; Guerra 
et al., 2002; MacBeth and Gumley, 2008; Payá et al., 2013; Stouten et al., 
2017). 
Nevertheless, the paucity of data on premorbid and cognitive fea-
tures by symptom dimensions in the whole psychosis spectrum (i.e. 
including both non-affective and affective psychotic disorders) is also 
caused by the absence of a systematic examination of manic symptoms 
in the literature (de Gracia Dominguez et al., 2009). Moreover, few 
studies have been based on large samples of patients at their first episode 
of psychosis (FEP), which minimise the confounding effect of the course 
of the disease on cognitive functioning and symptom presentation. In 
summary, to date, there are no studies that have used the same stand-
ardised methodology across multiple countries to evaluate psychopa-
thology at FEP and its relationship with premorbid and cognitive 
domains. 
In the present study, we used a large epidemiological multinational 
sample to investigate the relationship of both premorbid adjustment and 
current IQ on the one hand with a bifactor model of psychopathology at 
FEP on the other. Such a bifactor model comprises 1) a general psychosis 
factor, which accounts for the variance of all symptoms in the psychosis 
spectrum; and 2) specific symptom dimensions, that account for the 
variance due to specific subgroups of symptoms (i.e. positive, negative, 
disorganisation, manic, and depressive symptoms), independently from 
the general factor (Reininghaus et al., 2016; Reise et al., 2007). That is, 
while the general psychosis factor is a measure of the shared symptom 
presentation in this FEP sample, the specific symptom dimensions 
instead reflect its heterogeneity. 
We expected that premorbid and cognitive measures would account 
for some heterogeneity in symptom presentation at FEP. Therefore, 
these measures would explain more variation in specific symptom di-
mensions than in the general psychosis factor. 
More specifically, since the negative symptom dimension can be 
regarded as a clinical proxy of more neurodevelopmental impairment, 
we expected that worse premorbid adjustment and cognitive 
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functioning would be associated with more severe negative symptoms. 
Moreover, we examined if, as opposed to negative symptoms, the manic 
symptom dimension would indicate less neurodevelopmental impair-
ment, and therefore associated with a better premorbid adjustment and 
current cognitive functioning. 
2. Methods 
2.1. Study design 
Subjects were recruited between 01/05/2010 and 01/04/2015 
across centres in five different European countries (UK, Italy, Spain, 
Netherlands, France) and Brazil, as part of The European Network of 
National Schizophrenia Networks Studying Gene-Environment Interactions 
(EU-GEI) study (http://www.eu-gei.eu/) (CORDIS, 2019; European 
Network of National Networks studying Gene-Environment Interactions 
in Schizophrenia (EU-GEI) et al., 2014; Gayer-Anderson et al., 2020; 
Jongsma et al., 2018; van Os et al., 2008) with the overall aim to 
examine incidence rates and risk factors of psychotic disorders. 
2.2. Subjects 
Centrally trained researchers screened all potential FEP patients, 
presenting with a clinical diagnosis for an untreated FEP, even if long-
standing, at the mental health services and residents in each catchment 
area. Since this was a sample of consenting patients derived from an 
incidence study, inclusion criteria were age 18-64 years and having 
received operationalised diagnosis of a psychotic disorder (ICD-10: F20- 
F33) from their clinicians, and confirmed by the researchers, through 
the Operational Criteria in Studies of Psychotic Illness (OPCRIT) system. 
Inter-rater reliability was regularly assessed throughout the study. 
Exclusion criteria were psychotic symptoms precipitated by acute 
intoxication (ICD10: F1X.5), psychosis due to another medical condition 
(ICD10: F09) (World Health Organization, 1992), and a previous anti-
psychotic medication/prescription and/or previous contact with mental 
health services for psychosis. All local ethical committees approved the 
study (Gayer-Anderson et al., 2020; Jongsma et al., 2018). 
2.3. Measures 
We collected sociodemographic data using the Medical Research 
Council (MRC) sociodemographic schedule (Mallett et al., 2002). Psy-
chopathology was rated using the OPCRIT system, a 90-item semi- 
structured interview, of which 59 items concern psychopathology (Mc-
Guffin et al., 1991; Williams et al., 1996). The estimation of general and 
specific symptom dimensions’ scores was described in full in our pre-
vious study (Quattrone et al., 2019) and summarised in the supple-
mentary material. Briefly, the general psychosis factor score measured 
the covariance due to all psychopathology items, with stronger factor 
loadings from manic and delusional items. In parallel, the specific 
symptom dimension scores measured the remainder of variance due to 
subgroups of positive, negative, disorganisation, manic and depressive 
items. 
IQ was assessed by an abbreviation of the Wechsler Adult Intelli-
gence Scale–III (WAIS-III, ref), including four subtests: Digit Symbol 
Substitution (Processing Speed), Arithmetic (Working Memory), Block 
Design (Perceptual Reasoning) and Information (Verbal Comprehen-
sion) (Velthorst et al., 2013). 
Nine dimensions from the Premorbid Adjustment Scale (PAS) (Can-
non-Spoor et al., 1982; Rabinowitz et al., 2007) assessed premorbid 
social (PSF) and academic (PAF) adjustment in two distinct develop-
mental age-periods: childhood to age 11 and early adolescence (i.e. 12 to 
age 16) (Rabinowitz et al., 2002; van Mastrigt and Addington, 2002). 
PSF included social withdrawal (<11 and 12-16 years), peer relation-
ships (<11 and 12-16 years), and ability to form socio-sexual relation-
ships (designed from 12 to age 16 only). PAF included scholastic 
performance (<11 and 12-16 years), and adaptation to school (<11 and 
12-16 years) (Ferraro et al., 2019). IQ calculation and the PAS reduction 
of dimensions (Ferraro et al., 2019) included in these analyses were 
described in our previous studies, also summarised in the supplementary 
material. 
Date of onset and weeks of untreated psychosis (DUP) were recorder 
by the Nottingham Onset Scale (Singh et al., 2005). Thus, for retro-
spective interviews, we ensured that they referred to the pre-onset 
period (Gayer-Anderson et al., 2020). A medication list was recorded, 
including antipsychotic (AP) treatment, codified as AP free/ 1 AP /more 
than 1 AP. The Cannabis Experience Questionnaire (CEQEU-GEI) evalu-
ated the frequency of cannabis use (Di Forti et al., 2019). 
The core assessment (Gayer-Anderson et al., 2020) was administered 
as soon as the patient was compliant; psychopathology was rated by 
clinicians referring to any symptoms experienced within the first month 
of FEP; the WAIS and other retrospective measures (such as PAS) were 
proposed when the patient mental state was stable, as confirmed by his/ 
her clinicians. 
2.4. Statistical analysis 
The analysis was performed following two steps in SPSS 25 (IBM 
Corporation, 2017). 
First, we used multivariable analysis of the covariance (MANCOVA) 
to test the difference in symptom dimensions (the output), based on 
concomitant discrete and continuous independent variables (age, sex, 
self-reported ethnicity [white, black, or other ethnicities], study coun-
try, PSF, PAF, and IQ scores), so that the relationships found between 
one dimension and the predictors accounted (a) for those between the 
others, (b) and the intra-individual correlation of the dimensions in their 
severity. Given our previous reports in the EU-GEI study of an associa-
tion between frequency of lifetime cannabis use with more positive and 
fewer negative symptoms (Quattrone et al., 2020), as well as better PSF 
and IQ (Ferraro et al., 2019, 2013), we added this variable as an addi-
tional ordinal predictor (i.e. never use = 0; occasional/less than daily 
use = 1; daily use = 2) (Ferraro et al., 2019). Box's M test examined the 
covariance matrix, and effect size estimates were evaluated by Pillai's 
trace and partial eta squared. 
Second, we aimed to investigate if any specific cognitive function 
had a stronger relationship with the outcome than others. Thus, 
exploratory post hoc analyses were run by follow-up ANCOVAs with IQ 
subtests, PSF, PAF as the independent predictors, and age, sex, self- 
reported ethnicity, and study country as confounders, and those symp-
tom dimensions where IQ had an effect as the dependent variables 
(inserted once at a time). Moreover, we were interested to test frequency 
of cannabis use role in those specific symptom dimensions where it had 
an effect, and its interactions with premorbid adjustment and current IQ 
scores if appropriate (i.e., if both terms were predictive per se). All 
comparisons in MANCOVA and ANCOVAs were Bonferroni-adjusted and 
further corrected using the Benjamini-Hochberg (B–H) procedure, pre- 
determining a 5% chance of a false discovery rate. 
Following-up the Kravariti et al. (2012) study, we used a post hoc 
curve estimation regression to explore whether the association between 
manic symptoms and cognitive performance followed a U-shape 
(quadratic) better than a linear relationship, based on Akaike and 
Bayesian Information Criteria (AIC and BIC). 
Finally, we wanted to repeat the MANCOVA by including DUP and 
AP treatment as covariates, to avoid any influence of long-lasting 
symptomatology and pharmacotherapy on the relationship between 
the variables of interest. 
3. Results 
3.1. Descriptive characteristics 
785 out of 1130 FEP patients from the original sample (Di Forti et al., 
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2019; Gayer-Anderson et al., 2020) had a complete set of information for 
symptom dimensions, IQ, PAF and PSF, and confounding and mediating 
variables. The subjects included in this sample were not different from 
the rest of the sample in terms of sex (61.3% males vs. 62.6% males, 
χ2(1) = 0.18, p = 0.67) and ethnicity (65.2% white vs. 58.8% white, 
χ2(2) = 4.73, p = 0.09), but they were younger (Mean 30.5 (sd = 10.3) 
vs. Mean 33 (sd = 11.1)), t(2,1128) = 3.7, p < 0.001). This sample had a 
lower proportion of patients from the UK (18.5%vs. 29.3% vs.) and Italy 
(11.8% vs. 27.2), as compared to the rest of the sample (χ2(5) = 94.8, p 
< 0.001). 
The mean age of the sample was 30.5 years (sd = 10.3), and the 
majority of the subjects were male (61.3% [N = 481]), white (65.2% [N 
= 512]), unemployed (56.7% [N = 445]), single (64.5% [N = 506]), and 
living with their parents or another family (58.1% [N = 456]) at the time 
of the interview. 42.7% (N = 335), had a first-level (professional, A- 
level) education. Supplementary Table 1 mean IQ of the study sample 
was 85.5 (sd = 18.1), and 66% (N = 518) of the subjects had used 
cannabis in their lifetime (Table 1). 75.5% (N = 593) of the patients 
received a diagnosis of “non-affective psychosis” (32.3%, N = 253 
schizophrenia) as detailed in Supplementary Table 1. Supplementary 
Table 2 describes the crude correlations between symptom dimensions 
and premorbid adjustment and current cognitive functioning. 
3.2. Predictive model for symptom dimensions by premorbid adjustment 
and cognition 
The MANCOVA analysis showed that IQ [Pillai = 0.019, F(6, 765) =
2.52; p = 0.020; partial η2 = 0.019] and premorbid social impairment 
(PSF) [Pillai = 0.032, F(6, 765) = 4.26; p < 0.001; partial η2 = 0.032] 
had an overall discriminant effect of a small magnitude on symptom 
dimensions, whereas academic premorbid impairment (PAF) did not 
[Pillai = 0.007, F(6, 765) = 0.93; p = 0.468; partial η2 = 0.007] 
(Table 2). 
Positive symptoms were slightly more common in individuals with 
lower IQ (B = -0.005, 95% C.I. -0.01, 0.0, p = 0.033). Negative symp-
toms were associated with lower IQ, although the magnitude of the 
association was very small (B = -0.005, 95% C.I. -0.01, -0.001, p =
0.014), and with worse PSF (B = -0.12, 95% C.I. -0.18, -0.06, p < 0.001). 
By contrast, manic symptoms were slightly more common in patients 
with higher IQ (B = 0.005, 95% C.I. 0.0004, 0.009, p = 0.03), and better 
PSF (B = 0.07, 95% C.I. 0.14, 0.01, p = 0.023). Depressive symptoms 
were more common in individuals with lower PSF (B = -0.09, 95% C.I. 
-0.15, -0.03, p = 0.032). Finally, we did not observe an association be-
tween IQ and/or PSF with the general psychosis factor or the dis-
organisation symptom dimensions (Table 3). 
A small effect on the model was observed for cannabis use on 
symptom dimensions [Pillai = 0.027, F(12, 1532) = 1.76; p = 0.049; 
partial η2 = 0.014] (Table 1). Specifically, positive symptoms were 
higher in individuals with daily use of cannabis, compared with never 
(B = − 0.270, 95% C.I. − 0.478, − 0.061, p = 0.011) and occasional users 
(B = − 0.256, 95% C.I. − 0.442, − 0.07, p = 0.007). Other variables’ ef-
fects are described in the supplementary material. 
A post hoc exploratory analysis was performed removing IQ from the 
predictors to examine whether the lack of association between PAF and 
the scores on any of the symptom dimensions was due to the current 
cognitive measures in the model, but this was not the case [Pillai =
0.012, (6, 766) = 1.5; p = 0.168; partial η2 = 0.012]. 
A longer DUP was associated with more positive symptoms (r =
0.170, p < 0.001) and with lower scores at the general symptom 
dimension (r = -0.124, p = 0.001). Moreover, a longer DUP correlated 
with lower PSF (r = -0.124, p = 0.001), but not with differences in IQ (r 
= 0.005, p = 0.901). However, the results described above did not 
change when adjusted by the DUP and the number of AP taken at the 
interview time (see supplementary material). 
3.3. The specific effect of IQ subtests on symptom dimensions 
We then examined the effect of processing speed, working memory, 
perceptual reasoning, and verbal comprehension on negative, manic and 
positive dimensions, with the additional confounder effect of frequency 
of cannabis use on the positive symptom dimension only. 
Associations of small magnitude were observed for perceptual 
reasoning with a lower score on the negative symptom dimension (B =
− 0.09, 95% C.I. − 0.17, − 0.01, p = 0.023) and a higher score on the 
manic symptom dimension (B = 0.10, 95% C.I. 0.02, 0.18, p = 0.014). 
In a post hoc analysis, we found that the quadratic term (AIC =
2266.346; BIC = 2317.972) did not improve the model compared with 
the linear one (AIC = 2265.142; BIC = 2316.768). Thus, we maintained 
the assumption of a linear relationship between manic symptoms and 
perceptual reasoning. 
Associations of small magnitude were also observed for worse pro-
cessing speed (B = − 0.12, 95% C.I. − 0.02, 0.004, p = 0.003) and 
Table 1 
Descriptive characteristics of the sample.  
Country, N (%)   
UK  145 (18.5) 
Netherlands  167 (21.3) 
Spain  168 (21.4) 
France  64 (8.2) 
Italy  93 (11.8) 
Brazil  148 (18.9) 
Age, Mean (sd)  30.5 (10.3) 
Gender, N (%)   
Males  481 (61.3) 
Females  304 (38.7) 
Self-reported ethnicity, N (%)   
White  512 (65.2) 
Black  117 (14.9) 
Other  156 (19.9) 
Occupation, N (%)   
Employed, student  327 (41.7) 
Unemployed, economically inactive  445 (56.7) 
Education, N (%)   
University and post-graduated  130 (16.6) 
First-level (job related, A-level)  335 (42.7) 
Compulsory education  206 (26.2) 
No education  110 (14.0) 
Relationship Status, N (%)   
Married, in a steady relationship  229 (29.2) 
Divorced, separated, widowed  48 (6.1) 
Single  506 (64.5) 
Living Status, N (%)   
Partner, with children, friends  210 (26.8) 
Alone  112 (14.3) 
Parents, other family, other  456 (58.1) 
Lifetime frequency of cannabis use, N (%)   
Never  267 (34.0) 
Occasionally  274 (34.9) 
Everyday  244 (31.1) 
IQ, Mean (sd)  85.5 (18.1)  
Table 2 
Multivariate tests discriminant effectsa.  
Effect Pillai's 
Trace 




Intercept  0.04  5.253  6  765  <0.001  0.04 
Country  0.321  8.8  30  3845  <0.001  0.064 
Gender  0.019  2.49  6  765  0.022  0.019 
Ethnicity  0.029  1.872  12  1532  0.034  0.014 
Age  0.051  6.912  6  765  <0.001  0.051 
PSF  0.032  4.266  6  765  <0.001  0.032 
PAF  0.007  0.937  6  765  0.468  0.007 
IQ  0.019  2.527  6  765  0.02  0.019 
Frequency of 
cannabis use  
0.027  1.763  12  1532  0.049  0.014  
a Design: Intercept + country + gender + ethnicity + age + PSF + PAF + IQ +
frequency of cannabis use. 
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working memory (B = − 0.10, 95% C.I. − 0.18, − 0.01, p = 0.024) and a 
higher score on the positive symptom dimension. 
Higher frequency of cannabis use was moderately associated with 
higher positive symptom scores (never vs daily use = B = 0.25, 95% CI 
0.04, 0.46, p = 0.016; occasional vs daily use = B = 0.24, 95% CI 0.05, 
0.42, p = 0.010). 
We found evidence for a positive symptom-by-cannabis use inter-
action effect, suggesting that processing speed is differently associated 
with positive symptoms, depending on frequency of cannabis-use (F(2, 
767) = 3.1, p = 0.047, partial η2 = 0.008). Specifically, cannabis daily- 
users had more positive symptoms than never- (B = 0.273, 95% C.I. 
0.02, 0.52, p = 0.030) and occasional users (B = 0.245, 95% C.I. 0.019, 
0.47, p = 0.029), regardless of their processing speed scores. However, 
within the group of occasional cannabis users, positive symptoms were 
fewer when processing speed deficits were less pronounced (B = − 0.22, 
95% C.I. − 0.4, − 0.03, p = 0.017, partial η2 = 0.007) (Supplementary- 
Fig. 1). 
4. Discussion 
First, we found that premorbid social functioning was independently 
associated with specific patterns of symptom presentation. FEP patients 
with lower levels of social adjustment presented with more negative and 
depressive symptoms, whereas those with higher levels of social 
adjustment presented with more manic symptoms. 
Second, we found an independent, small association between IQ and 
symptom dimensions. Specifically, patients with current lower IQ pre-
sented with slightly more negative and positive symptoms and fewer 
manic symptoms compared with those with higher IQ scores. However, 
these associations were of small magnitude. 
Third, when considering IQ sub-tests, we found that specific cogni-
tive sub-domains drove the association between IQ and symptom pre-
sentation. That is, while lower processing speed and working memory 
were associated with more positive symptoms, lower perceptual 
reasoning was associated with more negative and fewer manic 
symptoms. 
4.1. Manic and negative symptoms 
Our findings are congruent with previous studies focused on in-
dividuals at risk for psychosis (Tarbox et al., 2013) and around the onset 
of first psychosis. (Payá et al., 2013; Chang et al., 2013; Horton et al., 
2015), suggesting that variation in cognitive and premorbid social fea-
tures is associated with different early trajectories of premorbid 
adjustment. 
In our study, higher IQ and better premorbid sociability were asso-
ciated with more manic symptoms and fewer negative symptoms, which 
is in line with the suggested heterogeneity in neurodevelopmental pre-
disposition in psychosis. Indeed, negative symptoms at FEP are often 
considered a marker of early developmental impairment (Murray and 
Castle, 1991). 
When considering diagnoses, more severe neurodevelopmental 
impairment has been extensively reported in schizophrenia than in bi-
polar disorders (Allardyce et al., 2007; Bucci et al., 2018a; Koenen et al., 
2009; Mollon et al., 2018; Torrent et al., 2018; Trotta et al., 2015). 
Altogether, these elements support the hypothesis of a continuous dis-
tribution of neurodevelopmental impairment across the psychosis 
spectrum and within disorders; to some extent, the categories of 
Table 3 
Parameter estimates in the predictive model for symptom dimensions by PSF, PAF and IQ.  
Dependent variable Parametera B SE t p-Value 95% C.I. Partial Eta2 
Lower Bound Upper Bound 
GENERAL Intercept  0.049  0.205  0.24  0.81  − 0.353  0.451  0.000 
PSF  0.047  0.027  1.707  0.088  − 0.007  0.101  0.004 
PAF  0.042  0.031  1.339  0.181  − 0.019  0.103  0.002 
IQ  − 0.001  0.002  − 0.536  0.592  − 0.005  0.003  0.000 
Daily vs never use  − 0.1  0.082  − 1.216  0.224  − 0.262  0.061  0.002 
Daily vs occasional use  − 0.078  0.073  − 1.068  0.286  − 0.222  0.066  0.001 
POSITIVE Intercept  0.313  0.264  1.187  0.236  − 0.205  0.832  0.002 
PSF  − 0.041  0.035  − 1.155  0.248  − 0.11  0.029  0.002 
PAF  − 0.04  0.04  − 0.984  0.325  − 0.119  0.039  0.001 
IQ  − 0.005  0.002  − 2.133  0.033  − 0.01  0.000  0.006 
Daily vs never use  − 0.27  0.106  − 2.539  0.011  − 0.478  − 0.061  0.008 
Daily vs occasional use  − 0.256  0.095  − 2.705  0.007  − 0.442  − 0.07  0.009 
NEGATIVE Intercept  0.383  0.243  1.577  0.115  − 0.094  0.859  0.003 
PSF  − 0.124  0.033  − 3.821  0.000  − 0.188  − 0.06  0.019 
PAF  − 0.033  0.037  − 0.89  0.374  − 0.105  0.04  0.001 
IQ  − 0.005  0.002  − 2.452  0.014  − 0.01  − 0.001  0.008 
Daily vs never use  0.19  0,098  1.946  0.052  − 0.002  0.381  0,005 
Daily vs occasional use  0.018  0,087  0.202  0.84  − 0.153  0.188  0 
DISORGANIZATION Intercept  0.458  0.238  1.924  0.055  − 0.009  0.926  0.005 
PSF  − 0.056  0.032  − 1.746  0.081  − 0.118  0.007  0.004 
PAF  0.041  0.036  1.132  0.258  − 0.03  0.112  0.002 
IQ  − 0.003  0.002  − 1.497  0.135  − 0.008  0.001  0.003 
Daily vs never use  − 0.09  0.096  − 0.936  0.349  − 0.278  0.098  0.001 
Daily vs occasional use  − 0.072  0.085  − 0.843  0.4  − 0.239  0.096  0.001 
MANIA Intercept  0.365  0.246  1.485  0.138  − 0.118  0.848  0.003 
PSF  0.075  0.033  2.275  0.023  0.01  0.14  0.007 
PAF  − 0.014  0.037  − 0.374  0.709  − 0.088  0.06  0.000 
IQ  0.005  0.002  2.172  0.03  0.000  0.009  0.006 
Daily vs never use  − 0.161  0.099  − 1.628  0.104  − 0.355  0.033  0.003 
Daily vs occasional use  0.038  0,088  0.436  0.663  − 0.135  0.212  0 
DEPRESSION Intercept  − 0.244  0.236  − 1.033  0.302  − 0.708  0.22  0.001 
PSF  − 0.093  0.032  − 2.941  0.003  − 0.155  − 0.031  0.011 
PAF  0.013  0.036  0.37  0.712  − 0.057  0.084  0.000 
IQ  − 0.002  0.002  − 1.122  0.262  − 0.007  0.002  0.002 
Daily vs never use  0.058  0,095  0.612  0.541  − 0.128  0.245  0 
Daily vs occasional use  0.065  0,085  0.765  0.444  − 0.101  0.231  0.001 
Gender, Age, ethnicity and Country parameters are showed in the Supplementary Table 4. 
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schizophrenia and bipolar disorder might approximately catch the high 
and low extremes of this distribution (Arango et al., 2014; Demjaha 
et al., 2012b; Murray et al., 2004; Parellada et al., 2017). 
The association between IQ and negative and manic dimensions was 
largely driven by the perceptual-reasoning domain, which is related to 
perceptual abnormalities (Morita et al., 2019; Silverstein and Keane, 
2011) and to the speed of thinking process (Scheiber et al., 2017), which 
is accelerated in manic episodes and decelerated in negative states. 
Perceptual-reasoning is also considered a proxy of ‘general ability index’ 
of intelligence, able to overcome subjects’ linguistic problems (Green 
et al., 2008), and it is generally more impaired in schizophrenia 
compared with other psychotic disorders. 
We reported this association using a delimited negative symptom 
dimension composed of restrictive and blunted affect and poverty of 
speech. 
These findings are in line with one previous report on FEP patients 
concerning negative and manic symptoms (Kravariti et al., 2012). 
However, unlike Kravariti et al. (2012), we did not find an inverse U- 
shape relationship between cognition and manic symptoms. Of note, we 
choose to do not exclude patients with IQ < 70; this contributed to lower 
the median IQ of the sample, but it made our findings reflecting the real 
clinical practice. 
4.2. Positive symptoms 
Positive symptoms were associated with lower current IQ but not 
with worse premorbid adjustment. This relationship was driven by 
lower processing speed and worse working memory, which are well- 
recognised early neuropsychological markers of schizophrenia (Dick-
inson et al., 2007; Forbes et al., 2009; Lee and Park, 2005; Silver et al., 
2003). On the other hand, a deficit in working memory has been re-
ported both in individuals with schizophrenia and bipolar disorder 
currently experiencing auditory verbal hallucinations (Jenkins et al., 
2018) that may be linked to dysfunctions in verbal memory encoding 
(Gisselgård et al., 2014). 
Processing speed may relate to a broad range of cognitive dysfunc-
tions, more than merely low-speed (Ayesa-Arriola et al., 2016; Rodrí-
guez-Sánchez et al., 2007), and it implies encoding abilities as well 
(Mathias et al., 2017). 
Indeed, these cognitive sub-domains are probably associated to fluid 
intelligence (Fry and Hale, 2000; Neisser et al., 1996; Yuan et al., 2006), 
and their functioning increases in concert as the effect of the cognitive- 
developmental cascade (Fry and Hale, 2000). Thus, their dysfunction 
might precede or be contextual to the diagnosis and can contribute to the 
aberrant coding typical of positive symptoms (Freeman et al., 2014; 
Laloyaux et al., 2018; Zhu et al., 2018). Given the result of our supple-
mentary analysis, including the effect of AP medication, it is unlikely 
that these results are related to the use of antipsychotics at the time of 
the interview. 
Of note, fluid intelligence is not only state-, but also and trait- 
dependent. Hence, we cannot firmly establish a causal direction of this 
association between positive symptoms and lower processing speed and 
general IQ. However, more insight on it can derive from the interactive 
effects of patterns of cannabis use. 
The frequency of cannabis use was associated with more prominent 
positive symptoms at FEP (Ringen et al., 2016; Seddon et al., 2016), in a 
dose-response effect (Quattrone et al., 2020). Particularly, we found an 
interaction between cannabis use and processing speed in predicting 
positive symptoms in the group of occasional cannabis users. Such a 
group of patients may present with the most cognitively-related positive 
symptoms, i.e. being not related to neurodevelopmental impairment, 
compared with never users (Ferraro et al., 2019), as well as to long- 
lasting or residual effects of cannabis use, compared with daily users 
(Quattrone et al., 2020) (see supplementary material). Therefore, it is 
intriguing to speculate whether cannabis use could be considered as a 
transdiagnostic proxy of less neurodevelopmental impairment in 
psychotic disorders. Notably, never users presented with the lowest 
positive symptoms, regardless of their processing speed abilities, in line 
with the finding of a predominance of negative symptoms in this sub-
group (Pope et al., 2021; Quattrone et al., 2020). 
4.3. Depressive symptoms 
Worse premorbid sociability but not current cognition was associ-
ated with depressive symptoms, in line with previous studies (Tarbox 
et al., 2012). These findings support a difference between mood down-
regulation and flat affect, the second being more a cognitively-related 
deficit in the emotion-processing, while depressive symptom dimen-
sion in psychosis could be part of a motivational impairment, indepen-
dent from negative symptoms (Culbreth et al., 2018), which needs 
further attention from both a research and clinical point of view 
(Upthegrove et al., 2017). 
4.4. Disorganised symptoms 
Disorganisation is often indicative of a lower psychosocial func-
tioning (Minor et al., 2015; Minor and Lysaker, 2014); however, in our 
sample, we did not find any relationship of current cognitive charac-
teristics and premorbid adjustment with disorganisation symptoms at 
FEP. Consistent with previous literature (Díaz-Caneja et al., 2015; Drake 
et al., 2016; Galderisi et al., 2012; Morgan et al., 2008; Petruzzelli et al., 
2018), men in our sample showed more disorganised and negative 
symptoms than women; furthermore, an earlier age-of-onset was related 
to more disorganised and negative and fewer depressive symptoms, in 
line with hypothesised sex-related neurodevelopmental characteristics 
of psychosis (Murray and Castle, 1991; Riecher-Rössler and Häfner, 
2000; Seeman, 1997). 
4.5. General psychosis factor 
Finally, we found that the general psychosis factor was not associ-
ated with cognitive and premorbid features. This firstly suggests that 
current cognitive characteristics and premorbid adjustment at FEP may 
reflect specific symptom-developmental predisposition as opposed to 
unspecific, common psychopathology. Moreover, this finding should be 
put in the context of the general factor conceptualisation in the EU-GEI 
FEP sample (Quattrone et al., 2019), where the identified general psy-
chosis factor catch the shared characteristics across diagnostic cate-
gories of non-affective and affective psychosis (Quattrone et al., 2019). 
Of note, the conceptualisation of a general factor in our sample, and its 
relationship with cognitive and premorbid features, may be different 
from samples that include all psychiatric diagnoses (Kotov et al., 2020), 
or the general population (Caspi et al., 2020; Murphy et al., 2020). In 
such scenarios, the general factor reflects a wider range of symptoms 
than psychosis, and it may therefore serve as a more general index of 
psychopathology. 
5. Limitations 
This study has two main limitations. First, we used a narrow negative 
symptom dimension due to the limited coverage of negative symptoms 
of the OPCRIT (Quattrone et al., 2019). Still, our findings are in line with 
previous literature, and they are, overall, coherent with a developmental 
risk model of psychosis (Murray et al., 2017). Second, we cannot exclude 
some extent of recall bias in referring to premorbid adjustment using the 
PAS. However, the PAS is the most validated tool for measuring pre-
morbid adjustment in patients who have been diagnosed with a psy-
chotic disorder (Brill et al., 2008; Rabinowitz et al., 2007). Finally, our 
PAS measures stop at age 16 (early adolescence), to prevent overlap 
with illness onset, while previous studies reported the most significant 
deterioration between 16 and 18 years (late adolescence) for the aca-
demic factor (PAF) (Allen et al., 2013; Strauss et al., 2012). This could be 
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responsible for the counterintuitive finding of a lack of association be-
tween a worse PAF and symptomatological markers of neuro-
developmental impairment, such as negative or depressive symptoms. 
On the other hand, one of these studies (Strauss et al., 2012) reported a 
greater premorbid PAF impairment in those with less PSF deficiency, 
thus suggesting a non-linear association between these two factors. 
Third, this is a multinational study and, as expected, we observed dif-
ferences in symptom dimension scores across countries. We consider 
these differences as reflecting the genuine variation of psychopathology 
in different contexts. Indeed, all researchers underwent a psychopa-
thology OPCRIT rating and inter-rater reliability was calculated before 
and during the study. Moreover, country, used as a confounder, did not 
affect our main findings, which are in turn more generalizable due to the 
multinational design of the EU-GEI study. 
6. Conclusions 
Our findings support the use of symptom dimensions in psychosis 
research and clinical practice. Indeed, the plausibility of such contin-
uous phenotypes depends on both their validity and the degree of useful 
information that can be derived by their examination. 
From a research perspective, we evaluated a dimensional symptom- 
developmental model of psychosis. In our sample, cognitive abilities and 
premorbid functioning contributed to the heterogeneous expression of 
psychosis at FEP. Assuming that dysfunction in current cognitive and 
premorbid social abilities are indicative of more neurodevelopment 
impairment in psychosis, we may speculate that our findings reflect the 
existence of different neurodevelopmental predispositions in psychosis, 
resulting in differential symptomatology at FEP. 
From a clinical perspective, the identification of premorbid and 
cognitive features associated with symptom presentation may be rele-
vant to overcome certain issues with psychiatric nosology. In addition to 
the traditional diagnoses, mental health professionals should be 
encouraged to formulate enhanced clinical impressions, integrating 
their evaluation of symptoms at FEP with information on personal his-
tory and cognitive functioning. Our findings suggest that premorbid 
academic poor adjustment could be a less sensitive risk-factor than an 
early social poor adjustment, which would require further attention and 
consideration in future studies, where the use of both these measured 
would be highly recommended. 
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Galega de Medicina Xenómica, Hospital Clínico Universitario, Chou-
pana s/n, 15782 Santiago de Compostela, Spain), David Fraguas MD, 
PhD, Department of Child and Adolescent Psychiatry, Hospital General 
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de la Santé et de la Recherche Médicale (INSERM), U955, Equipe 15, 51 
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Selten, J.P., Turner, C., Arango, C., Tarricone, I., Berardi, D., Tortelli, A., Llorca, P. 
M., De Haan, L., Bobes, J., Bernardo, M., Sanjuán, J., Santos, J.L., Arrojo, M., Del- 
Ben, C.M., Menezes, P.R., Murray, R.M., Rutten, B.P., Jones, P.B., Van Os, J., 
Morgan, C., Kirkbride, J.B., Reininghaus, U., Di Forti, M., Hubbard, K., Beards, S., 
Stilo, S.A., Tripoli, G., Parellada, M., Cuadrado, P., Solano, J.J.R., Carracedo, A., 
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Häfner, H., 2005. Association between functioning in adolescence prior to first 
admission for schizophrenia and affective disorders and patterns of hospitalizations 
thereafter. Schizophr. Res. 73, 185–191. https://doi.org/10.1016/j. 
schres.2004.08.008. 
Rabinowitz, J., Harvey, P.D., Eerdekens, M., Davidson, M., 2006. Premorbid functioning 
and treatment response in recent-onset schizophrenia. Br. J. Psychiatry 189, 31–35. 
https://doi.org/10.1192/bjp.bp.105.013276. 
Rabinowitz, J., Levine, S.Z., Brill, N., Bromet, E.J., 2007. The premorbid adjustment scale 
structured interview (PAS-SI): preliminary findings. Schizophr. Res. 90, 255–257. 
https://doi.org/10.1016/j.schres.2006.10.008. 
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